Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia

Clinical Study of Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment for Adult High-risk Acute Lymphoblastic Leukemia

To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.

To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.

Inclusion Criteria:

• Adult patients with high-risk acute B-lymphoblastic leukemia
• Complete remission was achieved after induction chemotherapy, and autologous CD19-CAR-T was successfully prepared
• Eligible for autologous hematopoietic stem cell transplantation
• No major organ dysfunction

Exclusion Criteria:

• Combined with malignant tumors of other organs
• With a serious infection that is not under control
• Syphilis, AIDS, hepatitis B, hepatitis C, any one of them positive
• Patients who have had an allergic reaction to the drugs used in this study or similar drugs
• Other patients deemed unsuitable for inclusion by the investigators